Navigation Links
Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program
Date:12/10/2009

EMERYVILLE, Calif., Dec. 10 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host an Analyst Briefing on December 17, 2009 at 8:30 a.m. ET.

The briefing, hosted by Onyx management, will provide an overview of its development program and feature presentations on multiple tumor types by external clinical investigators and members of management.

The live webcast, to begin at 8:30 a.m. ET, will be available on the Onyx website at:

http://www.onyx-pharm.com/view.cfm/32/Event-Calendar

A replay of the webcast will be available on the Onyx website through December 31, 2009.

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals, Inc., is developing and marketing Nexavar® (sorafenib) tablets a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a next-generation proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors, and ONX 0801, a targeted alpha-folate inhibitor, currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.

SOURCE Onyx Pharmaceuticals, Inc.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009
2. Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2010
3. Cubist Pharmaceuticals Becomes First Company to Implement Integrated Reprints Desk Document Delivery and QUOSA Scientific Literature Workflow Solution
4. Anesiva Completes Sale of its Zingo(TM) Assets to Powder Pharmaceuticals and Lees Pharmaceuticals
5. BioCryst Pharmaceuticals Elects Charles A. Sanders to its Board of Directors
6. ADVENTRX Pharmaceuticals to Present at the Lippert/Heilshorn Life Sciences Virtual Conference
7. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
8. Rib-X Pharmaceuticals Expands License Agreement with Yale University on New Ribosome Technology
9. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
10. Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals Universal Flu Vaccine
11. Onyx Pharmaceuticals to Host American Society of Hematology (ASH) Investor Teleconference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016   Acsis , a ... that leading IT market research and advisory firm IDC ... the IDC MarketScape: Worldwide Pharmaceutical Track and Trace Software ... report provides an assessment of the capabilities and business ... trace software market. Logo - http://photos.prnewswire.com/prnh/20160427/360791LOGO ...
(Date:4/27/2016)... Inc. (Nasdaq: HOLX ) announced today ... quarter ended March 26, 2016.  GAAP diluted earnings ... non-GAAP diluted EPS of $0.47 increased 14.6%.  Revenue ... basis, and 6.3% on a constant currency basis.  ... highlighted by 14.6% growth in non-GAAP EPS," said ...
(Date:4/27/2016)... 27, 2016 Elekta today announced ... will be the focal point of seven scientific presentations ... Society for Radiotherapy & Oncology, taking place April 29 ... state-of-the-art radiotherapy system and a high-field MRI scanner with ... the patient,s anatomy in real time. The MR-linac is ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 30, 2016 , ... Mercy College is expanding its Graduate ... programs will be expanding due to high demand: Master of Business Administration (MBA), Master ... this summer. , School of Business Graduate Program Chair Dr. Ray Manganelli ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... Council for Graduate Medical Education (ACGME) that it has received accreditation for its ... accreditation of three residency programs that Memorial is currently pursuing, including Pediatrics and ...
(Date:4/29/2016)... ... April 29, 2016 , ... On Tuesday, April 26, ... the Southeast, celebrated the signature of Gov. Nathan Deal on SB 258, the “Rural ... (R - Cumming), offers a 70% tax credit to individuals and corporations which donate ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... reveals that infants born with severe congenital diaphragmatic hernia have better survival rates ... with congenital diaphragmatic hernia (CDH)—a condition where the diaphragm fails to form completely, ...
Breaking Medicine News(10 mins):